Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source

Faculty: Richard Lafayette, MD, FACP


Faculty: Ankana Daga, MD

Complement-mediated kidney diseases such as C3 glomerulopathy (C3G) continue to present significant diagnostic and therapeutic challenges in nephrology for both adult and pediatric patients. Among children, this rare disease can progress to end-stage kidney disease within 10 years of diagnosis. Traditional treatment options include supportive care and immunotherapies, but both approaches are only modestly effective in reducing proteinuria. The approval of complement inhibitors, particularly those directed to C3, is a major treatment advance for C3G, revolutionizing the care of patients in this setting. In this activity, experts in the field of nephrology review the clinical evidence for these therapies and offer practical tips regarding their optimal use in pediatric patients.